Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity.
about
HIF-1alpha and HIF-2alpha are differentially activated in distinct cell populations in retinal ischaemiaExpression of vascular endothelial growth factor and pigment epithelial-derived factor in a rat model of retinopathy of prematurityThe mouse retina as an angiogenesis model.Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis)Mitigation of oxygen-induced retinopathy in α2β1 integrin-deficient mice.A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo.Macrophage metalloelastase (MMP-12) deficiency mitigates retinal inflammation and pathological angiogenesis in ischemic retinopathy.Rap1 GTPase activation and barrier enhancement in rpe inhibits choroidal neovascularization in vivo.Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog.Vascular endothelial growth factor antagonist therapy for retinopathy of prematurityExpression and role of VEGF in the adult retinal pigment epitheliumInner retinal oxygen metabolism in the 50/10 oxygen-induced retinopathy model.Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model.Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurityNeutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus diseaseProlyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes.Short hairpin RNA-mediated knockdown of VEGFA in Müller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity.Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity.The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model.Targeting Müller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity.Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity.Protective effect of maternal uteroplacental insufficiency on oxygen-induced retinopathy in offspring: removing bias of premature birthMechanisms and management of retinopathy of prematurity.Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression.Signaling pathways triggered by oxidative stress that mediate features of severe retinopathy of prematurity.Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity.The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model.Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.Association of retinal vascular endothelial growth factor with avascular retina in a rat model of retinopathy of prematurity.The progress of prophylactic treatment in retinopathy of prematurity.
P2860
Q28474375-24A4B503-8489-4ED2-856C-4EB91BE4174CQ28583644-6EE485C7-0711-4194-A46C-13DB3AF0EAD7Q30495106-74C0295E-369F-4C6A-943E-90460C6038C1Q33787955-CC4F1CBD-39AB-4B2C-8084-93C7B906C261Q33915935-428C7CC8-DFE7-4863-8580-E86851137264Q34208338-D3EBCBE0-94D9-459E-9028-80D63AB54E2CQ34534458-8C8D83D2-0A55-4E1D-BF25-D2F7C8CF512EQ34988793-389226FD-74AD-443A-887A-6303CBDE5D36Q35221047-66D14AC2-D6D1-4D2A-97C1-B7AB067D0D86Q35473907-F70899F3-8CF1-44FB-B72E-F0FCA5FF6230Q35648344-7DE4E2F9-BBED-43FA-BB02-2ED325E5ABE3Q36291702-13231519-21F4-4A9A-BA2C-6AE9D59CB9F7Q36618068-A8A85DDC-2C6F-4B3B-8198-424B069D260CQ36752978-31A415CA-D47A-4F9C-9B2B-23CD05017E77Q36761991-C8300091-7AC0-4E30-85C6-CF2E869DCDEBQ37018797-0177C8D6-0E9F-4321-9895-816FF3A0632DQ37049770-1B65B73A-66D2-4B30-9DA3-BE505D26A3C1Q37149035-8F7A12DA-4D1F-46A2-9428-A5C46E6BCF93Q37561227-0AC3901A-1534-4C68-A58F-ACBA9A94AB67Q37565247-CDA06226-1B82-4779-BF75-9F28B64A9EA4Q37577214-946948D9-A3AC-4304-BBD3-710707DBE44CQ37623450-6C2B205B-59AB-44C3-B062-F4DDADF2FAB2Q37640165-43AE0D6C-93F1-43FE-A701-04E0AB750A2DQ38069895-970CECCA-093B-4DEB-8595-C1C8B05C77D7Q38848653-60DDA183-82F5-4A59-9EA0-A98D41591E58Q42044757-39DC2840-CDFF-45FD-815F-830B78D442F6Q42081421-1698F25C-DC1C-4990-AC37-BB220AC4222DQ42155672-A7EFE9E4-7C1F-4773-94FA-CE7BA847A1CBQ42155684-54B398D2-F573-4768-8787-FCD2E87CE661Q42577163-54374BDE-D922-4C13-8318-A9CB8EDD83B5Q42942158-BA0A53EE-2D29-4C82-8215-51E9581359F8Q54999086-90356E75-1E10-4137-A48C-DE50529D302F
P2860
Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Neutralizing antibody to VEGF ...... of retinopathy of prematurity.
@en
type
label
Neutralizing antibody to VEGF ...... of retinopathy of prematurity.
@en
prefLabel
Neutralizing antibody to VEGF ...... of retinopathy of prematurity.
@en
P2093
P2860
P1433
P1476
Neutralizing antibody to VEGF ...... of retinopathy of prematurity
@en
P2093
Ahbineet Uppal
D Martiniuk
L J Peterson
M Elizabeth Hartnett
P2860
P304
P577
2008-02-11T00:00:00Z